← Torna allo Screener

TG Therapeutics

TGTX Mid Cap

Healthcare · Biotechnology

Aggiornato: May 2, 2026, 22:05 UTC

28,87 €
+0.21% oggi
52W: 21,56 € – 34,97 €
52W Low: 21,56 € Posizione: 54.6% 52W High: 34,97 €

Metriche Chiave

P/E Ratio
12.22x
Rapporto P/E
Forward P/E
14.06x
P/E Forward
P/S Ratio
8.77x
Prezzo/Vendite
EV/EBITDA
41.43x
Valore Impresa/EBITDA
Rendimento Dividendi
Rendimento annuale da dividendi
Cap. di Mercato
4,6 Mrd. €
Capitalizzazione di Mercato
Crescita Ricavi
78%
Crescita Ricavi Anno su Anno
Margine di Profitto
72.56%
Margine Netto
ROE
102.75%
Return on Equity
Beta
1.75
Sensibilità al mercato
Interesse Corto
23.48%
% del flottante in vendita allo scoperto
Volume Medio
1,879,559
Volume Medio Giornaliero

Analisi della Valutazione

Segnale
Sottovalutata
vs. P/E medio S&P 500 (24,7x)
Consenso degli Analisti
Comprare
7 analisti
Prezzo Obiettivo Medio
38,02 €
+31.67% potenziale
Range Obiettivo
12,80 € – 51,18 €

Informazioni sull'Azienda

Settore: Healthcare Industria: Biotechnology Paese: United States Dipendenti: 399 Borsa: NCM

TG Therapeutics Stock at a Glance

TG Therapeutics (TGTX) is currently trading at 28,87 € with a market capitalization of 4,6 Mrd. €. The trailing P/E ratio stands at 12.22x, with a forward P/E of 14.06x. The 52-week range spans from 21,56 € to 34,97 €; the current price is 17.4% below the yearly high. Year-over-year revenue growth stands at +78.0%. The net profit margin stands at 72.56%.

💰 Dividendo

TG Therapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Raccomandazioni degli Analisti

7 analysts rate TG Therapeutics (TGTX) on consensus: Comprare. The average price target is 38,02 €, implying +31.67% from the current price. Analyst price targets range from 12,80 € to 51,18 €.

Tesi di Investimento: Punti di Forza e Debolezze

Punti di Forza
  • Strong revenue growth of 78% YoY
  • Profitable with 72.56% net margin
  • High return on equity (102.75% ROE)
  • High gross margin of 83.66% — indicates pricing power
  • Analyst consensus: Buy
  • Currently flagged as undervalued
  • Solid balance sheet with low debt (D/E 39.26)
Debolezze
  • High short interest (23.48%)
  • Negative free cash flow

Panoramica Tecnica

MM 50 Giorni
27,39 €
+5.42% vs. prezzo
MM 200 Giorni
27,19 €
+6.21% vs. prezzo
Sotto Massimo 52S
−17.4%
34,97 €
Sopra Minimo 52S
+33.9%
21,56 €

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profilo di Rischio

Rischio di Mercato (Beta)
1.75 · Elevated
Moves more than the overall market
Short Interest
23.48% · High
% del flottante in vendita allo scoperto
Debt-to-Equity
39.26 · Low
Debito totale / patrimonio

The data points to above-average price swings, elevated short interest (23.48%).

Dati di Trading

50-Day MA: 27,39 €
200-Day MA: 27,19 €
Volume: 1,471,848
Volume Medio: 1,879,559
Ratio Corto: 13.35
Rapporto P/B: 7.49x
Debito/Patrimonio: 39.26x
Flusso di Cassa Libero: -37.515.037 €

Where can I buy TG Therapeutics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Scroll to Top